Tabula Rasa HealthCare Completes the Sale of SinfoníaRx and DoseMeRx

Tabula Rasa HealthCare, Inc.® (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that it completed the sale of its SinfoníaRx business to Cureatr, following the sale of its DoseMeRx business to an affiliate of Fairlong Capital LLC earlier this year. The combined proceeds are $11 million.

“The successful sale of these two businesses, along with the sale of PrescribeWellness in August 2022, completes the strategic divestitures that we announced last year, advancing our commitment to focus on our core value-based markets,” said Brian Adams, President and Interim CEO of TRHC.

TRHC completed the sale of DoseMeRx, an advanced precision dosing tool, on January 20, 2023. The sale of TRHC’s Medication Therapy Management (MTM) business, SinfoníaRx, closed on March 2, 2023.

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ: TRHC) provides medication safety solutions that empower healthcare professionals and consumers to optimize medication regimens, combatting medication overload and reducing adverse drug events. TRHC’s proprietary technology solutions, including MedWise®, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC’s extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and at-risk provider groups to help drive value-based care. For more information, visit TRHC.com.